| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 214.5 | 191.7 | 184.5 |
| Other income | 8.7 | 11.1 | 10.3 |
| Total income | 223.2 | 202.8 | 194.8 |
| Profit before exceptional items & tax | 68.8 | 53.5 | 59.5 |
| Profit before tax | 68.8 | 53.5 | 59.5 |
| Net profit | 51.2 | 38.6 | 44.7 |
| Operating margin | 30.8% | 26.4% | 30.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.50% |
|---|---|
| Net profit, quarter on quarter | +32.60% |
| Revenue, year on year | +16.30% |
| Operating profit, year on year | +22.20% |
| Operating profit, quarter on quarter | +41.70% |
NSE results filing, NSE: ADVENZYMES. Figures extracted from the filing.
Advanced Enzyme Technologies Ltd: key numbers
- Share price
- ₹263.55
- Market cap
- ₹2,951 Cr
- Revenue (annual)
- ₹745.8 Cr
- Net profit (annual)
- ₹168.7 Cr
- P/E (TTM)
- 17.8×Sector 45.9×
- Promoter holding
- 43.56%+0.32% QoQ
- FII holding
- 26.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advanced Enzyme Technologies Ltd
All →Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme Technologies bought back 54,455 equity shares via Emkay Global on October 29, 2026 at an average of ₹263.76. Cumulative buyback stands at 24,10,906 shares under the ongoing open-market programme.
- Value
- ₹1.44 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme bought back 64,583 shares on 28-10-2026 at an average ₹262.49, totalling 23,56,451 shares to date. Purchases were made via Emkay Global on the open market.
- Value
- ₹1.70 Cr
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme bought back 29,115 shares on October 27, 2026, worth about ₹0.75 Crore. Cumulative buyback stands at 22,91,868 shares under its open-market programme.
- Value
- ₹0.75 Cr
Advanced Enzyme Technologies Board Meeting Date
Advanced Enzyme Technologies will hold a board meeting on 31 October 2026 to approve Q2 and H1 FY27 unaudited results. The trading window stays closed until 2 November 2026.
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme Technologies bought back 58,326 equity shares at an average price of ₹263.3605 per share on October 22, 2026.
- Value
- ₹1.54 Cr